Acta clinica Croatica, Vol. 58. No. 3., 2019.
Original scientific paper
https://doi.org/10.20471/acc.2019.58.03.08
Prognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients
Josip Mihić
orcid.org/0000-0001-9780-1688
; Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Krešimir Rotim
; Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Majda Vučić
; Department of Pathology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Ida Hude Dragičević
; Division of Hematology, Department of Internal Medicine, Zagreb University Hospital Centre, Zagreb, Croatia
Marta Borić
; Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Liborija Lugović-Mihić
orcid.org/0000-0001-7494-5742
; Department of Dermatovenereology, Allergy and Clinical Immunology Unit, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia
Abstract
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 (47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 1:250) were used to evaluate neovascularization. Statisti-cal analysis showed negative correlation between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter survival), but there was no correlation between neovascularization de-termined by CD105 in GBM and patient survival. Thus, significant individual predictors of longer survival were lower expression of CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results obtained suggested the possible role of CD44 in the progression and tumor neovas-cularization of GBM.
Keywords
Glioblastoma; Brain neoplasms; Prognosis; Immunohistochemistry; CD44 protein, human; En-doglin
Hrčak ID:
230177
URI
Publication date:
1.9.2019.
Visits: 1.919 *